Glofitamab in Real Life

The Lymphoma Academic Research Organisation

Status: Enrolling

Conditions: Large B-cell Lymphoma

Treatments: Drug: Glofitamab

Study type: Observational

Funder types: Other

Identifiers

NCT06994169

GloRel

Details and patient eligibility

About

To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation [8, 15].

Enrollment: 250 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024
• patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab
• adult patient
• patient who is informed of the study and who did not oppose to their data collection

Exclusion criteria

• none

Trial design

250 participants in 1 patient group

Patients treated in EPA

Description:

Patients treated in Expanded Access Program to Glofitamab

Treatment:

Drug: Glofitamab